Literature DB >> 15302953

Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope.

Sally A Sharpe1, Alethea Cope1, Stuart Dowall1, Neil Berry2, Claire Ham2, Jonathan L Heeney3, Donna Hopkins1, Linda Easterbrook1, Mike Dennis1, Neil Almond2, Martin Cranage4.   

Abstract

To further investigate mechanisms of protective immunity that are induced by live, attenuated simian immunodeficiency virus (SIV), three macaques were infected with SIVmacGX2, a nef-disrupted molecular clone. In two of these animals, which expressed the MamuA*01 major histocompatibility complex class I allele, loss of functional activity against an SIV-Gag-encoded immunodominant cytotoxic T lymphocyte (CTL) epitope was observed following prolonged infection. Nonetheless, all three animals were resistant to challenge with an uncloned pool of wild-type SIVmac, whereas four naïve controls became infected. Tetramer staining revealed the rapid generation of CD8+ T-cell responses against gag- and tat-encoded immunodominant epitopes in MamuA*01+ challenge controls. The dynamics of these T-cell responses to the wild-type virus were similar to those observed following primary infection of the vaccine group with attenuated virus. In contrast, neither tetramer staining nor gamma interferon ELISpot assay revealed an immediate, systemic, anamnestic response in the wild-type-challenged, attenuated SIV-infected animals. Functional CTL capacity had not been lost in this group, as lytic activity was still evident 17 weeks after challenge. Both attenuated and wild-type viruses induced a disseminated CD8+ T-cell response, which was of a higher magnitude in lymphoid tissues than in the periphery. These results suggest that, at least as measured in the periphery, protection against wild-type infection that is induced by live, attenuated SIV is not dependent on a rechallenge-driven expansion of immunodominant epitope-specific CD8+ T cells and, therefore, pre-existing activity may be sufficient to prevent superinfection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302953     DOI: 10.1099/vir.0.80050-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus.

Authors:  Richard Stebbings; Neil Berry; Herman Waldmann; Pru Bird; Geoff Hale; Jim Stott; David North; Robin Hull; Joanna Hall; Jenny Lines; Stuart Brown; Nikki D'Arcy; Leanne Davis; William Elsley; Cherry Edwards; Deborah Ferguson; Jane Allen; Neil Almond
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus.

Authors:  Meritxell Genescà; Pamela J Skinner; Jung Joo Hong; Jun Li; Ding Lu; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

3.  Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection.

Authors:  M-D Salha; R Cheynier; R Halwani; H McGrath; T Y Langaee; B Yassine Diab; J Fournier; M Parenteau; J Edgar; D Ko; A Sherring; D Bogdanovic; R-P Sekaly; E W Rud
Journal:  Virology       Date:  2008-08-01       Impact factor: 3.616

4.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

5.  Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.

Authors:  Wendy W Yeh; Pimkwan Jaru-Ampornpan; Daiva Nevidomskyte; Mohammed Asmal; Srinivas S Rao; Adam P Buzby; David C Montefiori; Bette T Korber; Norman L Letvin
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

6.  Vaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+ T cells.

Authors:  Bo Li; Neil Berry; Claire Ham; Deborah Ferguson; Deborah Smith; Joanna Hall; Mark Page; Ruby Quartey-Papafio; William Elsley; Mark Robinson; Neil Almond; Richard Stebbings
Journal:  Retrovirology       Date:  2011-02-03       Impact factor: 4.602

7.  Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques.

Authors:  Neil Berry; Claire Ham; Edward T Mee; Nicola J Rose; Giada Mattiuzzo; Adrian Jenkins; Mark Page; William Elsley; Mark Robinson; Deborah Smith; Deborah Ferguson; Greg Towers; Neil Almond; Richard Stebbings
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

8.  T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virus.

Authors:  Ghulam Nabi; Vladimir Temchura; Claudius Grossmann; Seraphin Kuate; Matthias Tenbusch; Klaus Überla
Journal:  Retrovirology       Date:  2012-05-14       Impact factor: 4.602

9.  ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.

Authors:  Michael D Alpert; Jackson D Harvey; W Anderson Lauer; R Keith Reeves; Michael Piatak; Angela Carville; Keith G Mansfield; Jeffrey D Lifson; Wenjun Li; Ronald C Desrosiers; R Paul Johnson; David T Evans
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

Review 10.  Retroviral superinfection resistance.

Authors:  Micha Nethe; Ben Berkhout; Antoinette C van der Kuyl
Journal:  Retrovirology       Date:  2005-08-18       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.